10/15/2018
Mark S. Patterson, MBBS, PhD, MD, MRCP; René J. Van Der Schaaf, MD, PhD; Jean-Paul R. Herrman, MD, PhD; Ton Slagboom, MD; Maarten A. Vink, MD, PhD; Moniek Maarse, MD; Rob Adams, MSc; Robbert J. de Winter, MD, PhD; Nicola S. Vos, MD; Giovanni Amoroso, MD, PhD
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12...